Drug intelligence / Profile preview

lactobacillus salivarius V4II-90

Development stage: Unknown
Lead developer: ProbiSearch
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus salivarius V4II-90 is a specific probiotic bacterial strain investigated for its ability to reduce Group B Streptococcus (GBS) colonization in pregnant women. GBS, or *Streptococcus agalactiae*, is a significant cause of neonatal infections, and maternal colonization is a primary risk factor. The strain is intended to be administered orally to modulate the vaginal and rectal microbiota, utilizing mechanisms such as competitive exclusion, production of organic acids (like lactic acid), and potentially bacteriocins to inhibit GBS growth. A randomized, double-blind, placebo-controlled trial (NCT03669094) has evaluated the efficacy of this strain in GBS-positive pregnant women to lower the incidence of colonization before delivery, thereby potentially reducing the need for intrapartum antibiotic prophylaxis.

Other names: Lactobacillus salivarius V4II-90L. salivarius V4II-90

Beyond the preview

Go deeper on lactobacillus salivarius V4II-90.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus salivarius V4II-90.

Explore the full profile